Erin Lavelle
No más puestos en curso
Fortuna: - $ al 31/03/2024
Historial de carrera de Erin Lavelle
Antiguos cargos conocidos de Erin Lavelle.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ELIEM THERAPEUTICS, INC. | Chief Operating Officer | 01/10/2020 | 10/03/2023 |
Director of Finance/CFO | 01/10/2020 | 10/03/2023 | |
ALDER BIOPHARMACEUTICALS, INC. | Chief Operating Officer | 16/04/2018 | 01/02/2020 |
AMGEN INC. | Corporate Officer/Principal | 01/06/2016 | 01/03/2018 |
Sales & Marketing | 01/07/2003 | 01/06/2016 | |
Vitaeris, Inc.
Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Director/Board Member | - | - |
NEUROGENE INC. | Director/Board Member | 01/06/2020 | - |
Independent Dir/Board Member | 01/06/2020 | - |
Formación de Erin Lavelle.
Yale University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 6 |
Canadá | 2 |
Operativa
Chief Operating Officer | 2 |
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 6 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
AMGEN INC. | Health Technology |
ELIEM THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Vitaeris, Inc.
Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Health Technology |
Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
- Bolsa de valores
- Insiders
- Erin Lavelle
- Experiencia